Skip to content
Open access

Integrated Multi‐Omics Analysis Identifies PDK4 and ACOT1 as Metabolic Hub Genes Associated With Myocardial Fibrosis in Diabetic Cardiomyopathy

Jan 2026 · Journal of Diabetes Research · Vol 2026 · 0 citations · 36 references
Medicine

TL;DR

PDK4 and ACOT1 are identified as evolutionarily conserved metabolic hub genes associated with myocardial fibrosis in DCM, suggesting a putative “metabolism–fibrosis axis” and providing potential therapeutic targets.

Abstract

Diabetic cardiomyopathy (DCM) is a critical pathological driver of heart failure in diabetic patients, primarily characterized by progressive myocardial fibrosis. Nevertheless, the core molecular network linking upstream metabolic dysregulation to the aberrant activation of downstream cardiac fibroblasts remains largely elusive. In this study, we combined in vivo and in vitro approaches with bioinformatics analysis. A high‐fat diet‐induced mouse model of diabetic myocardial fibrosis was established, and transcriptome sequencing was performed to screen for hub genes, which were subsequently validated in two independent DCM datasets. Single‐cell RNA sequencing revealed that PDK4 and ACOT1 were upregulated in cardiac fibroblasts under pathological conditions. In vitro experiments confirmed that high glucose induced the expression of PDK4, ACOT1, and fibrotic markers in human primary cardiac fibroblasts. Molecular docking predicted a potential interaction between PDK4 and ACOT1. Collectively, our findings identify PDK4 and ACOT1 as evolutionarily conserved metabolic hub genes associated with myocardial fibrosis in DCM, suggesting a putative “metabolism–fibrosis axis” and providing potential therapeutic targets.

Read PDF

Similar papers

Sep 2026

Weighted gene co-expression network reveals CCND1 as a promising biomarker and therapeutic target for myocardial fibrosis in hypertrophic cardiomyopathy.

BACKGROUND Myocardial fibrosis represents a critical prognostic indicator of poor outcomes in hypertrophic cardiomyopathy (HCM), frequently predisposing patients to lethal ventricular arrhythmias and progressive heart failure. However, the upstream molecular mechanisms driving cardiac fibrogenesis in HCM remain largely...

Lei Chang, Chen-Yi Gong, Zhi-Kang Wu et al. · 0 citations
Aug 2026

ATP6AP2 dysregulation as a central hub in DMD pathogenesis: An integrated multi-omics and therapeutic study.

It is demonstrated that TMZ mitigates dystrophic pathology by targeting the ATP6AP2 signaling axis and dampening macrophage-mediated inflammatory responses, highlighting its potential as a novel immunopharmacological therapeutic strategy for DMD.

Lin Zhou, Yu Zhang, Xinxin Tan et al. · 0 citations
Meta-analysis Sep 2026

Conserved hepatic RNA signatures across multiple cohorts reveal novel mechanistic clues for advanced fibrosis in human MASLD

Background: Fibrosis development in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) is a key indicator of disease progression and clinical outcome. Bulk and single-cell transcriptomics on human tissue have advanced understanding of fibrosis progression, but interstudy heterogeneity and li...

Jessica L. Maiers, Tie-Bing Liang, Tingbo Guo et al. · 0 citations
Open access Aug 2026

Acox2 deficiency induces cardiac dysfunction via cross-organ metabolic reprogramming in mice

Secondary cardiomyopathies are a major cause of heart failure (HF) with diverse etiologies and high mortality rates. For example, over 50% of patients with end-stage liver disease develop cardiac dysfunction, clinically termed cirrhotic cardiomyopathy (CCM). While serum metabolites mediating cross-organ communica...

Cancan Yao, Yan Chen, Zhouping Lu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.